Despite the approval of adjuvant osimertinib as a new step towards providing a more effective adjuvant therapy strategy for resected, EGFR-mutated NSCLC, it is important to mention that, from the perspective of third-party public healthcare payers, concerns about affordability and sustainability due to the high pricing of antitumor agents. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.